Selective anticancer drugs


NATURE REVIEWS | DRUG DISCOVERY VOLUME 1 | JULY 2002 | 491 The success of Glivec (Gleevec in the United States) in the treatment of chronic myelogenous leukaemia (CML) has provided the proof of principle that cancer can be treated by identifying the underlying molecular defects and designing drugs to correct them. Promising results in trials with other molecularly targeted drugs, such as Iressa and Tarceva (TABLE 1), have given further encouragement for such approaches. And with genomics and proteomics technologies poised to have an increasing impact, it seems a new era in anticancer therapy is beginning.

DOI: 10.1038/nrc900
Citations per Year

1,315 Citations

Semantic Scholar estimates that this publication has 1,315 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Atkins2002SelectiveAD, title={Selective anticancer drugs}, author={Joshua Atkins and Leland J. Gershell}, journal={Nature Reviews Cancer}, year={2002}, volume={2}, pages={645-646} }